Clinical Research
Evaluation of therapeutic markers and mechanism of Shuganjieyu capsule in treatment of depression
Zhao Yu, Li Yaojun, Wang Dan, Du Xinzhe, Gao Yao, Li Junxia, Liu Sha, Xu Yong
Published 2022-03-20
Cite as Chin J Behav Med & Brain Sci, 2022, 31(3): 235-240. DOI: 10.3760/cma.j.cn371468-20211111-00648
Abstract
ObjectiveTo compare the expression levels of candidate genes before and after Shuganjieyu capsule treatment, to analyze their correlation with depression symptoms and cognitive function, and to find and clarify the biomarkers related to the efficacy of Shuganjieyu capsule.
MethodsAmong 27 patients with mild to moderate depression (MMD), 24 items Hamilton depression rating scale (HAMD-24) was used to assess the severity of depression, Chinese revised Wechsler adult intelligence scale(WAIS-RC) and Chinese revised Wechsler memory scale(WMS) were used to assess cognitive function, and qRT-PCR was used to detect the expression levels of candidate genes in peripheral blood of patients with depression before and after treatment with Shuganjieyu capsule.SPSS 25.0 software was used for statistical analysis, paired t-test, non-parametric test, Spearman correlation analysis and receiver operating characteristic curve were used for data statistics.
ResultsThe symptoms of MMD patients were relieved after Shuganjieyu capsule treatment(HAMD scores: baseline 14.00(9.75, 18.25), 8-week 4.00(2.00, 7.25), Z=-4.462, P<0.01), and the verbal intelligence quotient(VIQ) of WMS was puomoved (VIQ scores: baseline (123.00±10.24), 8-week (128.00±6.77), t=4.372, P<0.01). The level of gene expression brain derived neurotrophic factor(BDNF) (baseline 1.68(0.92, 2.63), 8-week 2.30(1.47, 4.34), Z=-2.781, P=0.005), glial cell derived neurotrophic factor(GDNF) (baseline 0.74(0.31, 1.15), 8-week 0.97(0.50, 1.71), Z=-2.159, P=0.031), 5-hydroxytryptamine receptor 2A(HTR2A) (baseline 0.60(0.39, 1.60), 8-week 0.98(0.44, 2.29), Z=-1.994, P=0.046) and glutamate ionotropic receptor AMPA type subunit 1(GRIA1) (baseline 1.19(0.66, 2.40), 8-week 1.76(0.86, 4.13), Z=-2.756, P=0.006) was up-regulated after treatment.The change rate of BDNF expression were correlated with the score of HAMD-24 (r=-0.35, P=0.038) and performance intelligence quotient of WMS (r=0.40, P=0.022).
ConclusionsBDNF may be used as a therapeutic marker of Shuganjieyu capsule in the treatment of clinical symptoms and cognitive function of MMD patients, which is used to evaluate the efficacy of antidepressants.
Key words:
Shuganjieyu capsule; Depression; Brain derived neurotrophic factor; Evaluation of therapeutic markers; Pharmacology
Contributor Information
Zhao Yu
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
Li Yaojun
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Wang Dan
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Department of Physiology, Shanxi Medical University, Taiyuan 030001, China
Du Xinzhe
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Gao Yao
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Li Junxia
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Liu Sha
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
Xu Yong
Department of Mental Health, The First Hospital of Shanxi Medical University, Taiyuan 030001, China
